BioNTech SE Sponsored ADR (NASDAQ: BNTX - Get Free Report) CEO Ugur Sahin sold 36,209 shares of the

BioNTech SE Sponsored ADR (NASDAQ: BNTX - Get Free Report) CEO Ugur Sahin sold 27,000 shares of the

What happened BioNTech SE (NASDAQ: BNTX) said Chief Executive Officer and 10% owner Ugur Sahin sold

A new NIH-backed initiative to speed up personalized cancer vaccine development sent stocks like MRN

Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock trades at $207.80, up 5%, after its addition to

BioNTech now has more than 25 phase 2 and phase 3 oncology trials underway, with 15 phase 3 trials t

Morgan Stanley analyst Terence Flynn maintains BioNTech (NASDAQ:BNTX) with a Overweight and lower

What happened BioNTech SE (NASDAQ: BNTX) said Chief Executive Officer and 10% owner Ugur Sahin sold

Sanofi is carrying the Nuvaxovid COVID-19 shot into the fall vaccination season, and buyers are rewa

Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are trading as though the company's messenge

Buyers are stepping into Moderna (NASDAQ:MRNA | MRNA Price Prediction) shares, evidently. The move c

MRNA's respiratory vaccine expansion and promising oncology results offer potential growth as COVID-

Invivyd reported Phase 3 LIBERTY trial data for VYD2311, showing strong safety and enhanced COVID-19

German COVID‑19 vaccine maker BioNTech said on Monday it would close ​sites in Germany and Singapore

BioNTech SE Sponsored ADR (NASDAQ: BNTX - Get Free Report) CEO Ugur Sahin sold 30,000 shares of the

BioNTech SE Sponsored ADR (NASDAQ: BNTX - Get Free Report) CEO Ugur Sahin sold 39,000 shares of the

BioNTech SE Sponsored ADR (NASDAQ: BNTX - Get Free Report) CEO Ugur Sahin sold 46,000 shares of BioN

BioNTech SE Sponsored ADR (NASDAQ: BNTX - Get Free Report) CEO Ugur Sahin sold 33,000 shares of the

BioNTech recently experienced a clinical trial failure, followed by a clinical success several weeks

BMO Capital Markets downgraded BioNTech and lowered its price target for the stock. The move came af

Moderna (NASDAQ:MRNA | MRNA Price Prediction) shares are surging Monday morning after the company an

BioNTech (NASDAQ: BNTX - Get Free Report) and TScan Therapeutics (NASDAQ: TCRX - Get Free Report) ar

BioNTech terminated a Phase 2 study of autogene cevumeran in treating colorectal cancer. The setback

BioNTech (BNTX) Phase 3 data reveals gotistobart almost doubles survival in advanced lung cancer ove

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Analysts downgraded BioNTech, Gulfport Energy, Amgen and Best Buy; price targets fell for BioNTech a

Analysts raised targets for NOW, HOOD, MSTR, ABNB and CLYM, while cutting APP and IONS; ratings larg

BMO Capital analyst Evan Seigerman downgrades BioNTech (NASDAQ:BNTX) from Outperform to Market Pe

Canaccord Genuity analyst John Newman maintains BioNTech (NASDAQ:BNTX) with a Buy and lowers the

Take-Two Interactive Software, on Aug. 7, reported adjusted earnings were 35 cents per share, toppin

BioNTech shares are dropping Friday after the company decided to end its Phase 2 trial of autogene c

FDA approves updated COVID-19 vaccines for 2026-'27 season, targeting XFG variant. Limited eligi

2026-2027 COVID-19 vaccine formula targets the XFG variant, in line with FDA guidance to more closel

Arbutus Biopharma (ABUS) stock rises after announcing a $230M stock buyback via a modified Dutch auc

Merck & Moderna's partnership reports first Phase 3 success for personalized cancer vaccine,

Pumitamig plus B7H3-targeting elfetabart drozuntecan delivers the first data in lung cancer for any

Healthcare stocks saw mixed after-hours moves, with Moderna and Merck cooling after explosive gains

Pfizer Inc (NYSE:PFE) shares are trading higher Wednesday, moving in sympathy with mRNA cancer vacci

BioNTech stock rises as Merck and Moderna report positive cancer vaccine data, highlighting its indi

Dow Jones up 200 points on Wed. Estee Lauder & other top stocks record gains after reporting str

https://youtu.be/H_RititNE8U

Citigroup analyst Geoff Meacham maintains BioNTech (NASDAQ:BNTX) with a Buy and lowers the price

Evercore ISI Group analyst Cory Kasimov maintains BioNTech (NASDAQ:BNTX) with a Outperform and lo

BioNTech (NASDAQ:BNTX) lowers FY2026 sales outlook from $2.328 billion-$2.678 billion to $1.860 bill

BioNTech (NASDAQ:BNTX) reported quarterly losses of $(2.58) per share which missed the analyst conse

BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company"))) announced today that its Su

The formula targets the XFG variant, for active immunization to prevent COVID-19 caused by SARS-CoV-

Rep. Thomas Massie questions JD Vance's silence after the Trump CDC established a $1.24 Billion

Arbutus and its exclusive licensee, Genevant, filed three international lawsuits seeking to enforce

Morgan Stanley analyst Terence Flynn maintains BioNTech (NASDAQ:BNTX) with a Overweight and lower